Presentation is loading. Please wait.

Presentation is loading. Please wait.

Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy  Gian Piero Lozzi, MD, Gino Coletti,

Similar presentations


Presentation on theme: "Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy  Gian Piero Lozzi, MD, Gino Coletti,"— Presentation transcript:

1 Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy  Gian Piero Lozzi, MD, Gino Coletti, MD, Ketty Peris, MD  Journal of the American Academy of Dermatology  Volume 59, Issue 5, Pages S110-S112 (November 2008) DOI: /j.jaad Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Persistent primary cutaneous marginal zone lymphoma before (A) and after (B) two cycles of intralesional rituximab therapy. Journal of the American Academy of Dermatology  , S110-S112DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 A, Histopathologic findings of persistent primary cutaneous marginal zone lymphoma. B, Immunohistochemistry showed CD20 (L26)-negative phenotype. C, CD79a positivity reveals the B-cell immunophenotype of neoplastic cells. D, Kappa and E, lambda immunostaining showed that the neoplastic infiltrate exhibited a monoclonal expression of λ light chains. F, CD138 immunoreactivity revealed plasma cell component of neoplastic infiltrate. (A, Hematoxylin-eosin stain; original magnifications: A, ×4; B, ×4 [inset ×20]; C, ×4 [inset ×20]; D, E, and F,×4.) Journal of the American Academy of Dermatology  , S110-S112DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions


Download ppt "Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy  Gian Piero Lozzi, MD, Gino Coletti,"

Similar presentations


Ads by Google